Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HyperTargIPS-NK
- Development stage
- Preclinical
- Lead developer
- Magle Biopharma
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
HyperTargIPS-NK is an allogeneic induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell therapy being developed by Magle Biopharma. The platform utilizes engineered NK cells that can be modified using Chimeric Antigen Receptor (CAR) technology, non-CAR activation mechanisms, or TRUCK (T-cells redirected for universal cytokine killing)-style engineering to enhance anti-tumor activity and overcome the immunosuppressive tumor microenvironment. Currently in the preclinical stage, the therapy is being investigated for the treatment of solid tumors, including pancreatic cancer and glioblastoma, as well as hematological malignancies like acute myeloid leukemia (AML). The use of iPSCs as a starting material allows for a standardized, off-the-shelf approach to cell therapy, potentially improving scalability and reducing manufacturing costs compared to autologous therapies.
- Other names
- Hyper-Targ-IPS-NK-cell therapy
Beyond the preview
Go deeper on HyperTargIPS-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HyperTargIPS-NK.